Complement-Based Drug Development Summit leaderboard
  • Wednesday, September 30, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 9

Author

Pharma Journalist 9091 posts 0 comments

FDA Approves Regeneron’s Pasatru for Rare Bone Disorder FOP

Aug 21, 2026
Regeneron Pharmaceuticals has received U.S. Food and Drug Administration approval for Pasatru (garetosmab-grts), a new treatment for adults living with fibrodysplasia ossificans…
Read More...

FDA Grants Fast Track Status to Consano Bio’s Chronic Sciatica Drug

Aug 20, 2026
Consano Bio has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for C-1101, an investigational treatment being developed for chronic, painful…
Read More...

BioMarin to Acquire Alesta for Rare Bone Disease Drug

Aug 20, 2026
BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics in a deal aimed at adding a potential new treatment for hypophosphatasia (HPP), a rare genetic bone disease, to its…
Read More...

2nd T-Cell Engager for Autoimmune Disease Summit to Deliver 3 Days of Expert-Led Content to Advance…

Aug 19, 2026
Clinical translation insights to accelerate the development of differentiated autoimmune T-cell engager therapies. Following rapid progress in the autoimmune T-cell engager field,…
Read More...

Fulcrum and Slate Medicines Agree to $245 Million Merger

Aug 18, 2026
Fulcrum Therapeutics and Slate Medicines have agreed to combine in an all-stock merger that will create a company focused on developing new treatments for migraine and other headache…
Read More...

LEO Pharma Acquires Dersimelagon Rights for Rare Skin Diseases

Aug 18, 2026
LEO Pharma has agreed to acquire worldwide rights to dersimelagon from Tanabe Pharma in a deal that could reach up to $435 million in upfront and near-term milestone payments.…
Read More...

Sandoz and Henlius Expand Global Biosimilar Collaboration

Aug 17, 2026
Sandoz and Shanghai Henlius Biotech have entered into a major collaboration to develop, manufacture and commercialize biosimilar medicines, with the aim of expanding access to…
Read More...

FDA Grants Fast Track Status to Spevatamig for Biliary Cancer

Aug 17, 2026
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Phanes Therapeutics’ spevatamig for the treatment of patients with advanced and metastatic biliary…
Read More...

EMA Validates Pfizer and Valneva Lyme Disease Vaccine Application

Aug 17, 2026
The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for Pfizer and Valneva’s investigational Lyme disease vaccine, allowing the regulatory…
Read More...

FDA Approves Lantheus Tau PET Imaging Agent for Alzheimer’s

Aug 17, 2026
The U.S. Food and Drug Administration (FDA) has approved Lantheus Holdings’ TAUKLARIFY (florquinitau F 18 injection), a radiodiagnostic agent designed to help identify tau pathology in…
Read More...
Prev Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Semaglutide 2 mg Linked to Lower Cardiovascular Risk in Diabetes
  • Novo Nordisk Licenses HRS-1596 for Weekly Oral GLP-1 Therapy
  • AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
  • Tolerance Bio Licenses TLB-33 to Expand Thymic Health Pipeline
  • Direct RNA Binding Emerges as a Powerful Approach for Functional Disease Modulation

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.